Potassium Channel Dysfunction Redefines Restless legs syndrome: Mediated Mendelian Randomization and Enrichment Analysis Support Membrane Potential Polarization Disorder

Authors:

Xin Yao, MD

Department of Rehabilitation, Affiliated Yueqing Hospital of Wenzhou Medical University, Wenzhou 325000, China

Corresponding author:

Xin Yao, MD

Department of Rehabilitation, Affiliated Yueqing Hospital of Wenzhou Medical University, No. 338, Qingyuan Road, Yueqing City, Zhejiang Province, China 325600.

E-mail: yaoxinhongqiao@163.com

Tel: +86-13868328538

Abstract

Restless legs syndrome (RLS) is a common neurological disorder, that has not been clearly defined due to unclear pathophysiology, with only diagnostic criteria available. Opioids are approved for treatment-resistant RLS, long-term use may lead to tolerance and addiction issues. This study aimed to evaluate the therapeutic effects of opioids on RLS at different stages using Mendelian randomization analysis and temporal mediation model, and explore the potential pathogenesis of RLS. Linkage disequilibrium score correlation (LDSC) and bidirectional Mendelian randomization were conducted using genome-wide association study (GWAS) data for opioids use (N=78,808) and RLS (N=48,808). Mediated Mendelian randomization analysis was conducted using 1402 cerebrospinal fluid and brain metabolites as mediating factors. An idealized temporal mediation effect model was used to evaluate the efficacy of opioids at different stages, and identified four mediating factors and their pathways affecting therapeutic efficacy. Enrichment analysis and colocalization analysis were used to explore the potential mechanisms of diseases. This study suggested a bidirectional causal and genetic correlation between opioids use and RLS. The potassium channel-mediated and temporal mediation effect model demonstrated that short-term opioids use provides significant protective effects (OR=0.501, 95% CI: 0.273-0.918, P=0.025), while the total effect becomes marginally significant due to the offsetting masking effects of risk mediating factors (OR=0.613, 95% CI: 0.359-1.046, P=0.072). Reverse MR analysis results showed that RLS is a risk factor for opioid use, supporting that patients with RLS driven by genetic susceptibility are more prone to opioid dependence. The pathogenesis of RLS mainly involves downregulation of potassium ion channels, upregulation of synaptic function and addiction mechanisms. These findings suggested that RLS is a membrane potential polarization disorder and may involve multiple systems.

Keywords: Restless legs syndrome; Opioids; Mendelian randomization; Membrane potential polarization disorder; Potassium ion channels; Cerebrospinal fluid and brain metabolites; Temporal mediation model; KCND3 gene

Introduction

Restless legs syndrome (RLS) affects approximately 7.12% of the global population (95% CI = 5.15–9.76), equating to 356.07 million affected individuals worldwide, and represents one of the most common neurological disorders1. Despite decades of research, the pathophysiology of RLS remains incompletely understood, without specific definition of RLS, only diagnostic criteria. The current theories are focusing primarily on brain iron deficiency and dopamine dysregulation2. However, these mechanisms cannot provide a global explanation and present obvious contradictions. For instance, cerebrospinal fluid levels of 3-Ortho-methyldopa (a dopamine metabolite) are elevated in RLS patients and positively correlated with disease severity, suggesting dopamine synthesis hyperactivity3. Additionally, imaging studies and autopsy findings indicate concurrent secondary dopamine receptor downregulation4. However, these theories cannot explain this phenomenon.

Cerebrospinal fluid examination and autopsy of patients with RLS show a deficiency of endogenous opioid[5,6]. Animal experiments show that knocking out opioid receptors can replicate the symptoms[7]. Opioids are approved for treatment-resistant RLS. Long-term follow-up studies demonstrate sustained efficacy without significant tolerance development[8,9]. However, the biological basis for this therapeutic efficacy and the causal relationship between opioids use and RLS development remain unclear.

Recent advances in Mendelian randomization (MR) methodology and the availability of large-scale genome-wide association study (GWAS) data provide unprecedented

opportunities to investigate causal relationships between exposures and outcomes[10]. Furthermore, CSF and brain tissue samples directly reflects the functional state of the brain, making CSF and brain metabolites particularly valuable as mediating factors for understanding neurological mechanisms underlying complex brain-related disorders.

In this study, a comprehensive MR framework was employed to investigate the causal relationship between opioid use and RLS, incorporating mediation analysis with 1,402 CSF and brain metabolites, and further explored the disease mechanisms underlying RLS. The findings led to the proposal of a novel pathophysiological framework—the "Multi-system Membrane Potential Polarization Dysfunction" hypothesis—that provided a unified explanation for RLS manifestations, therapeutic responses, comorbidity patterns, circadian rhythm alterations, iron metabolism disorders, dopaminergic system compensatory changes, and opioid treatment effects.

Methods

Study Design and Data Sources

A two-sample bidirectional MR study was conducted using summary statistics from large-scale GWAS. All genetic data were harmonized to the GRCh38 genome build to ensure consistency across analyses.

Opioid Use GWAS: GWAS summary statistics for opioid use (22,982 cases and 55,826 controls, N=78,808) were utilized from a European population study[11], which conducted a genome-wide association study (GWAS) on self-reported medication use in the UK Biobank cohort.

RLS GWAS: RLS data were obtained from the GWAS Catalog (GCST90435387) including 9,851 cases and 38,957 controls of European ancestry (N=48,808), derived from a large-scale genome-wide association meta-analysis[12].

CSF and brain Metabolomics GWAS: The GWAS summary data for 440 CSF metabolites and 962 brain tissue metabolites were obtained from the study by Cruchaga et al[13]. (CSF, n = 2602; brain tissue, n = 1,016).

Genetic Instrument Selection

Instrument Variable Quality Control Standards:

Stringent quality control criteria were implemented for all genetic instruments:

- Significance thresholds: $P<5\times10^{-8}$ for opioids use and RLS; $P<1\times10^{-5}$ for CSF and brain metabolites due to smaller sample sizes
- Minor allele frequency (MAF): >0.01 to ensure adequate statistical power
- F-statistics: >10 to ensure strong instrument strength, calculated using an improved formula: $R^2 = [2\times\beta^2\times EAF\times(1-EAF)] / [2\times\beta^2\times EAF\times(1-EAF) + 2\times SE^2\times N\times EAF\times(1-EAF)]$, then $F = [R^2\times(N-k-1)] / [(1-R^2)\times k]$, where β is the effect size, SE is the standard error, EAF is the effect allele frequency, N is the sample size, and k=1 for single SNP evaluation
- Linkage disequilibrium (LD) clumping: $r^2<0.001$, window=10,000kb using European reference panels (GRCh38)
- Palindromic SNP handling: Removal of A/T and G/C SNPs with ambiguous strand orientation and eaf close to 0.5 (0.45-0.55).

For opioid use, genetic instruments were identified using genome-wide significance threshold ($P<5\times10^{-8}$) and LD clumping. The only instrument was rs2618039, which maps to the KCND3 gene encoding a voltage-gated potassium channel (F-statistic=30.6).

For RLS, 7 independent genetic variants reaching genome-wide significance were selected, excluding rs7779977 due to outlier behavior and mapping to pseudogenes. The F-statistics for RLS instruments > 10.

For CSF and brain metabolites, a relaxed threshold ($P<1\times10^{-5}$) was used to retain sufficient genetic signals given smaller sample sizes, with all F-statistics > 10 across metabolites. To enhance the reliability of MR analysis, additional quality control measures were implemented to reduce the pleiotropy of instrumental variables by removing SNPs associated with 280 potential confounding factors, thus combining a relaxed significance threshold with stringent confounder exclusion strategies.

Statistical Analyses

Linkage Disequilibrium Score Correlation (LDSC)[14]: Genetic correlation between opioid use and RLS was estimated using LDSC with European LD reference panels.

Mendelian Randomization and Sensitivity Analyses: Two-sample bidirectional MR was performed using inverse variance weighted (IVW) method as primary analysis (Wald ratio method for single instrumental variable), supplemented by MR-Egger regression, weighted median method, and MR-PRESSO for pleiotropy detection and outlier correction[15]. Comprehensive sensitivity analyses included Cochran's Q statistic for heterogeneity testing[16], MR-Egger intercept test for horizontal pleiotropy detection[17], leave-one-out analysis for influential variant identification, and single SNP analysis for consistency assessment across instruments.

Mediation Analysis: Systematic mediation MR analysis was conducted testing 1,402 CSF and brain metabolites as potential mediators of the opioid-RLS relationship. The analysis employed a two-stage approach: Stage 1 examined exposure → mediator relationships using MR analysis, and Stage 2 assessed mediator → outcome relationships using MR analysis. Mediation proportions were calculated using the

formula: (indirect effect / total effect) × 100%. Negative mediation proportions indicate masking effects where opposing pathways counteract the direct causal effect, providing mechanistic explanation for marginal statistical significance in overall causal estimates.

Temporal Mediation Effect Model: A novel temporal framework was developed to explain the complex relationship between opioids use and RLS risk. This model incorporates the following key assumptions and components:

Model Assumptions:

1. Temporal heterogeneity: Opioid effects on RLS vary across different time periods
2. Multiple pathways: The protective and risk-promoting pathways may play a role at different stages.
3. Masking effects: Long-term risk-promoting mediators counteract and mask the constant direct protective effects mediated through potassium channel activation

Model Components:

1. Direct effect (τ): Constant protective effect through potassium channel activation (KCND3 gene), independent of time
2. Short-term mediation: Protective effects via:
- HPA axis suppression (reduced cortisol)
- Blood-brain barrier modulation (reduced urea)
- Immediate neuroprotective mechanisms
3. Long-term mediation: Risk effects via:
- Metabolic dysregulation (reduced fructose affecting dopamine reward)
- Tolerance development (ceramide accumulation)
- Neuroadaptive changes
4. Net effect calculation: Total effect = Direct effect + Short-term mediation - Long-term mediation

Mathematical Framework:

Total Effect = $\tau + \Sigma(\beta_{short\text{-}term} \times \alpha_{short\text{-}term}) - \Sigma(\beta_{long\text{-}term} \times \alpha_{long\text{-}term})$

Where β represents exposure-mediator effects and α represents mediator-outcome effects.

This model explains why total effect shows marginal significance (P=0.072) despite strong biological evidence for protective effects.

Genetic Colocalization Analysis:

To identify shared causal variants between CSF/brain metabolites and RLS, Bayesian genetic colocalization analysis[18] was performed using the coloc R package. For each significant CSF/brain metabolite identified in the mediation analysis, genomic regions of ±500kb around each instrumental variable SNP were defined. Within these regions, overlapping SNPs from both the metabolite GWAS and RLS GWAS datasets were extracted, requiring a minimum of 10 shared SNPs for analysis. The colocalization analysis calculated five posterior probabilities: PP.H0 (no association), PP.H1 (association with metabolite only), PP.H2 (association with RLS only), PP.H3 (independent associations), and PP.H4 (shared causal variant). PP.H4 > 0.75 was considered as strong evidence for genetic colocalization, indicating that the same causal variant influences both the metabolite level and RLS risk. This analysis helps distinguish between true shared genetic architecture and spurious associations due to linkage disequilibrium.

Enrichment Analysis Gene Selection:

For functional enrichment analysis, genes were extracted from genomic regions surrounding significant instrumental variables identified in the mediation analysis. Specifically, genes were derived from ±50kb flanking regions of SNPs serving as instrumental variables for CSF and brain metabolites that showed significant

associations (IVW P<0.05) with RLS in the Mendelian randomization analysis. This approach ensures that the enrichment analysis captures genes potentially influenced by the same regulatory mechanisms underlying the metabolite-RLS associations, providing biological context for the observed causal relationships.

A systematic four-step gene filtering strategy was implemented to ensure high-quality gene selection: (1) Duplicate removal: redundant gene entries were eliminated to avoid bias in enrichment analysis; (2) Functional annotation filtering: genes were queried through the GeneCards database (https://www.genecards.org/) to filter genes based on comprehensive functional annotations and disease relevance; (3) SNP-gene correspondence optimization: genes were prioritized to achieve one-to-one correspondence with SNPs where possible, reducing mapping ambiguity; (4) Protein-coding gene restriction: only protein-coding genes were retained to focus on functionally relevant targets with direct therapeutic implications. Through this rigorous filtering process, the final gene set was refined from an initial 2,809 SNP-mapped genes to 506 unique high-quality genes, comprising 247 upregulated genes and 259 downregulated genes based on effect direction analysis. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed to identify significantly enriched biological processes, cellular components, molecular functions, and metabolic pathways (p.adjust < 0.05), with differential enrichment analysis conducted separately for upregulated and downregulated gene sets to elucidate directional functional patterns underlying RLS pathophysiology.

Results

Genetic Correlation Between Opioid Use and RLS

LDSC analysis revealed significant positive genetic correlation between opioid use and RLS (rg=0.0983, SE=0.0467, Z=2.1040, P=0.0354), indicating shared genetic architecture.

Causal Effect of Opioid Use on RLS

The MR analysis using rs2618039 (mapping to KCND3 gene) as the instrumental variable with the Wald ratio method showed a potential protective effect of opioid use on RLS risk (OR=0.613, 95% CI: 0.359-1.046, P=0.072), which was slightly above the conventional 0.05 significance threshold.

Reverse Causation Analysis

MR analysis testing RLS as exposure and opioid use as outcome showed a significant causal effect (OR=1.066, 95% CI: 1.011-1.124, P=0.018), indicating that RLS increased the risk of opioid use, which supported bidirectional causality rather than unidirectional effects.

Mediation Analysis Results

Opioid Use → CSF and Brain Metabolites:
Using the Wald ratio method (single instrumental variable analysis), 51 significant associations between opioid use and CSF and brain metabolites (P<0.05) were retained after excluding 2 reverse causality relationships and 2 drug concentration-related exposures, from the initial 1,402 CSF and brain metabolites tested.

CSF and Brain Metabolites → RLS:
MR analysis identified 44 significant causal relationships between CSF and brain metabolites and RLS risk using the IVW method (P<0.05). 44 valid metabolite-RLS

associations without reverse causality relationship were included in subsequent mediation analysis.

Key Mediating Factors and Temporal Effects:

Bootstrap mediation analysis (10,000 iterations) identified four key CSF and brain mediators and the direct effect: cerebrospinal fluid cortisol (GCST90318234, a-effect β=-0.181, P=0.008; b-effect β=0.594, P=0.021; indirect effect=-0.108, mediation proportion=21.96%), urea (GCST90318260, a-effect β=-0.139, P=0.038; b-effect β=0.692, P=0.013; indirect effect=-0.096, mediation proportion=19.60%), fructose (GCST90318283, a-effect β=-0.124, P=0.005; b-effect β=-0.990, P=0.005; indirect effect=0.123, mediation proportion=-25.07%), and brain ceramides (GCST90318755, a-effect β=0.358, P=0.029; b-effect β=0.221, P=0.019; indirect effect=0.079, mediation proportion=-16.12%); the direct effect=-0.488.

The idealized temporal mediation model demonstrated that short-term opioid use provided significant protective effects (OR=0.501, 95% CI: 0.273-0.918, P=0.025), however, the effect decreased (OR=0.751, 95% CI: 0.411-1.371, P=0.351) when the risk mediation effect (fructose depletion and ceramide accumulation) was activated and the protective mediation (cortisol and urea suppression) effect was ineffective, explaining the attenuated overall causal effect.

Colocalization Analysis

Based on the colocalization analysis of 1402 CSF and brain metabolites and RLS, a strong colocalization evidence was identified for SNP rs11045279 between CSF 4-acetamidophenylglucuronide levels and RLS, which maps to the PDE3A gene region and involves reward mechanisms. The posterior probability of colocalization (PP.H4) reached 87.2%, exceeding the conventional threshold for robust genetic colocalization.

Enrichment Analysis

To further explore the pathogenesis of RLS, comprehensive GO and KEGG pathway enrichment analysis was conducted using 506 genes obtained from instrumental variable SNPs of significant Mendelian randomization results between CSF and brain metabolites and RLS.

Enrichment Analysis Overview:

The enrichment analysis included 506 total input genes with successful gene ID conversion rates approaching 100%. Among these, 247 genes showed upregulated effects and 259 genes demonstrated downregulated effects based on effect direction analysis. GO enrichment analysis revealed differential patterns across gene sets: for all genes combined, 45 biological processes (BP), 23 cellular components (CC), and 16 molecular functions (MF) reached statistical significance (p.adjust < 0.05). Differential analysis showed that upregulated genes contributed 2 significant BP terms, 18 CC terms, and 2 MF term, while downregulated genes contributed 22 BP terms, 7 CC terms, and 9 MF terms. KEGG pathway analysis identified 8 significantly enriched pathways for all genes, with upregulated genes showing 1 significant pathway and downregulated genes showing no independently significant pathways.

GO Enrichment Results:

The analysis revealed multiple potassium channel-related pathways were significantly enriched, including

potassium channel complex (GO:0034705, CC, 14 genes, p.adjust = 4.17e-05, fold enrichment = 5.87), voltage-gated potassium channel complex (GO:0008076, CC, 13 genes, p.adjust=4.17e-05, fold enrichment = 6.13) and potassium ion transmembrane transport (GO:0071805, BP, 18 genes, p.adjust = 0.0036, fold enrichment = 3.48), indicating that potassium ion channels play a crucial role.

Synaptic function-related pathways were prominently represented, with postsynaptic density membrane (GO:0098839, CC, 12 genes, p.adjust = 0.00277, fold enrichment = 3.99), synapse assembly (GO:0007416, BP, 20 genes, p.adjust = 0.00433, fold enrichment = 3.06) and positive regulation of axonogenesis (GO:0050772, BP, 10 genes, p.adjust = 0.00433, fold enrichment = 5.65), supporting the involvement of synapse in RLS pathophysiology.

Differential Functional Enrichment Analysis:

To better understand the directional effects of genetic variants on RLS pathophysiology, separate enrichment analyses were performed for upregulated and downregulated genes, revealing distinct functional patterns.

Upregulated Gene Functions:

Upregulated genes (247 genes) showed significant enrichment in synaptic function. The most prominent enriched functions included postsynaptic specialization membrane (GO:0099634, CC, 11 genes, p.adjust = 0.000197, fold enrichment = 6.04) and postsynaptic density membrane (GO:0098839, CC, 10 genes, p.adjust = 0.000197, fold enrichment = 6.8), indicating upregulation of synaptic function.

Downregulated Gene Functions:

Downregulated genes (259 genes) demonstrated a striking concentration in potassium channel regulation. The most significantly enriched biological process was regulation of potassium ion transmembrane transport (GO:1901379, 9 genes, p.adjust = 0.0024, fold enrichment = 8.57), and the cellular component enrichment was voltage-gated potassium channel complex (GO:0008076, 9 genes, p.adjust = 4.68e-04, fold enrichment=8.3), the molecular function enrichment was potassium channel regulator activity (GO:0015459, 7 genes, p.adjust = 0.00269, fold enrichment =9.49). Notably, membrane repolarization functions were significantly downregulated, including membrane repolarization (GO:0086009, BP, 6 genes: YWHAE/AKAP6/KCNN2/KCNIP1/KCNJ2/KCNE4, p.adjust = 0.0267, fold

enrichment=8.42) and membrane repolarization during cardiac muscle cell action potential (GO:0086013, 4 genes: YWHAE/KCNN2/KCNJ2/KCNE4, p.adjust = 0.0482, fold enrichment = 11.834).

Mechanistic Implications:

The differential enrichment pattern reveals a clear mechanistic dichotomy: while upregulated genes enhance synaptic function (potentially representing secondary synaptic change), downregulated genes primarily affect potassium channel function and membrane potential regulation (representing the core pathophysiological dysfunction). This pattern strongly supports the membrane potential polarization disorder hypothesis, where RLS is caused by impaired membrane repolarization ability mediated by downregulation of potassium channels, leading to neuronal overexcitation, secondary synaptic function upregulation, and enhanced signal transduction. This finding aligns with the mechanism by which opioids alleviate RLS symptoms through upregulation of the KCND3 gene.

KEGG Pathway Analysis:

8 KEGG pathways reached statistical significance (p.adjust < 0.05), with morphine addiction pathway showing the strongest enrichment (11 genes, p.adjust = 0.00336, fold enrichment = 4.98). Notably, when examining upregulated genes specifically, the fold enrichment for morphine addiction pathway further increased to 7.21 (8 genes, p.adjust = 0.00325), indicating enhanced addiction-related mechanisms in RLS pathophysiology. This finding is consistent with the addiction mechanism upregulation identified in the colocalization analysis with PDE3A. Other significantly enriched pathways included axon guidance, GABAergic synapse, serotonergic synapse, and cholinergic synapse.

These findings indicate that the pathogenesis of RLS involves potassium channel downregulation leading to membrane potential polarization or repolarization disorders,

synaptic function upregulation and enhanced addiction mechanisms, and may also secondarily cause dysregulation of multiple neurotransmitters.

Discussion

Mediated Mendelian randomization and Temporal Mediation Model

This study provided the first genetic evidence for a bidirectional causal relationship between opioid use and RLS, establishing a temporal mediation model to evaluate and validate the therapeutic effects of opioids. The identification of four key mediators—CSF cortisol, urea, fructose, and brain ceramides—provides unprecedented mechanistic insight into the temporal dynamics of opioid-RLS interactions. The temporal mediation model introduces time-dependent attributes to explain the complex therapeutic dynamics of opioids in RLS. This framework posits that opioids exert a constant direct protective effect through potassium channel activation (KCND3), while time-dependent mediating factors either enhance or counteract this effect at specific stages:

Short-term Protective Mechanisms:

- HPA axis suppression: Opioids reduce cerebrospinal fluid cortisol levels[19], thereby decreasing synaptic excitability[20,21] and providing protective effects.
- Blood-brain barrier modulation: Although the precise mechanism requires further investigation, decreased cerebrospinal fluid urea levels suggest altered blood-brain barrier permeability.

Long-term Risk Mechanisms:

- Metabolic dysregulation: Reduced cerebrospinal fluid fructose levels may impair dopamine-mediated reward mechanisms and exacerbate RLS symptoms, as fructose normally stimulates dopamine secretion[22].

- Tolerance development: Accumulation of brain ceramides can lead to opioid tolerance[23,24].

The temporal mediation model revealed that opioids exerted significant short-term protective effects against RLS (OR=0.501, 95% CI: 0.273-0.918, P=0.025), mediated primarily through KCND3-encoded voltage-gated potassium channels combined with protective mediating factors. However, long-term effects involve risk mediating factors mediated by metabolic dysregulation (fructose depletion and ceramide accumulation), which mask this protective signal, resulting in marginally significant overall causal estimates (OR=0.613, 95% CI: 0.359-1.046, P=0.072), despite strong biological evidence for therapeutic efficacy.

Pathophysiological Mechanisms: The Membrane Potential Polarization Disorder Hypothesis

Perhaps most importantly, the comprehensive functional enrichment analysis of 506 genes derived from 44 significant metabolite mediators provides compelling evidence for a novel pathophysiological framework: downregulation of potassium ion channel function and upregulation of synaptic function. Given the critical role of potassium ion channels in membrane potential formation, an innovative hypothesis of "Membrane Potential Polarization Disorder" can be used to explain RLS and related phenomena:

Central Role of Potassium Channel Dysfunction

The identification of rs2618039 in the KCND3 gene as the primary instrumental variable for opioids use provides direct genetic evidence linking voltage-gated potassium channels to RLS pathophysiology. KCND3 encodes Kv4.3, a voltage-gated potassium channel critical for action potential repolarization and membrane potential maintenance. The enrichment analysis demonstrates systematic downregulation of potassium channel-related pathways is involved in the occurrence of RLS.

Potassium channels are fundamental determinants of neuronal excitability through their control of resting membrane potential and firing threshold. Reduced potassium channel function shifts the resting potential toward depolarization, lowering the threshold for action potential initiation and converting neurons from Type II (high-threshold) to Type I (low-threshold) excitability patterns[25]. This dysfunction creates a cascade of membrane potential abnormalities: depolarized resting potential, prolonged repolarization time, enhanced neuronal excitability, and amplified synaptic signaling. The resulting membrane potential instability not only triggers classic RLS symptoms through aberrant activation of low-threshold sensory channels, but also affects multiple physiological systems. This explains why patients with RLS have a higher proportion of periodic limb movement disorders[26], increased fQRS angle on electrocardiogram[27], irritable bowel syndrome, and autonomic nervous system abnormalities[28].

Iron-Membrane Potential Interdependence

Iron is essential for the function of iron-sulfur clusters in mitochondrial electron transport chains, which generate the ATP necessary for Na+/K+-ATPase pump function. Iron deficiency impairs ATP production, leading to reduced Na+/K+-ATPase activity and subsequent membrane depolarization. Conversely, membrane depolarization significantly impairs iron transport efficiency across cellular membranes through multiple mechanisms. In the intestine, membrane depolarization reduces iron absorption capacity by disrupting the electrochemical gradients required for optimal function of iron transporters such as DMT1 (divalent metal transporter 1). DMT1 is a proton-coupled transporter that relies on the electrochemical gradient across cellular membranes for efficient iron uptake. At the tissue level, membrane depolarization creates iron transport barriers between different cellular compartments and across the blood-brain barrier. Ferroportin, the primary cellular iron exporter, works in conjunction with multicopper ferroxidases and depends on proper membrane potential for optimal iron export function. Membrane depolarization reduces the

driving force for ferroportin-mediated iron export, leading to cellular iron accumulation and paradoxical tissue iron deficiency—a phenomenon observed in RLS patients who show brain iron deficiency despite normal or elevated peripheral iron stores[29]. Animal studies demonstrate that opioid receptor knockout successfully replicates RLS symptoms while simultaneously inducing iron deficiency and anemia[7], providing direct experimental evidence for the membrane potential-iron transport interdependency in RLS pathophysiology.

This bidirectional relationship creates a pathological feedback loop: iron deficiency → membrane depolarization → impaired iron transport → worsening iron deficiency, which explains the mechanism by which iron supplementation works, as well as the dual complementary regulation of pain threshold observed in animal experiments by opioids and iron ions[30]. This hypothesis provides a mechanistic explanation for the well-established association between iron deficiency and RLS that has puzzled researchers for decades.

Dopaminergic System Secondary change and addiction mechanism

Parkinson's disease is considered a neurodegenerative disorder caused by declining dopamine levels[31]. Dopamine receptor agonists have therapeutic effects on both Parkinson's disease and RLS, leading to their association. However, there is no genetic evidence demonstrating a connection between these conditions[32]. Cerebrospinal fluid testing, neuroimaging and post-mortem studies in RLS patients consistently demonstrate dopaminergic system hyperactivity[3,4], and the latter two also demonstrate secondary dopamine receptor downregulation. The mediation analysis reveals that CSF fructose levels exert significant protective effects against RLS. Research demonstrates that fructose can stimulate dopamine secretion and participate in reward mechanisms[22]. These pieces of evidence suggest that the brain may attempt to counteract synaptic excitability changes caused by membrane potential dysfunction by compensatory secretion of dopamine. Recent experimental evidence provides direct mechanistic support for pain-induced dopaminergic compensation: a

pain-induced tonic hypodopaminergic state augments phasic dopamine release in the nucleus accumbens[33]. Dopamine may increase pain threshold by participating in central nervous system processing of pain signals[34]. For instance, Dopamine may reduce presynaptic glutamate release through the D2 receptor-G protein-cAMP/PKA pathway, and indirectly reduces synaptic excitability through the action of GABAergic interneurons in multiple dimensions[35]. However, long-term dopamine stimulation not only leads to the development of abnormally activated reward mechanisms into enhanced addiction mechanisms, but also results in a decrease in the number of receptors and a decrease in sensitivity, creating a sustained state of "dopamine hyperactivity-hypoallergenic". When dopamine levels do not reach the expected value at night, there is a relative deficiency, leading to the recovery of synaptic excitability. This explains the mechanisms underlying both the efficacy and failure of dopaminergic medications.

The probability of developing restless leg syndrome during opioid withdrawal is higher than during alcohol withdrawal[36,37], indicating that opioid may mediate the occurrence of restless leg syndrome through morphine addiction. The Mendelian randomization analysis of brain morphine levels (GCST90319128)13 and RLS provides genetic evidence supporting this clinical observation: brain morphine levels showed weak positive associations with RLS risk (OR=1.0338, 95% CI: 0.994-1.0753, P=0.0973 for current study GWAS12; OR=1.0571, 95% CI: 1.0062-1.1106, P=0.0275 for validation GWAS[38]). However, this is completely opposite to previous results. This may be due to the genetic instrument (rs2618039) primarily captures pharmacological effects without addiction mechanisms. This discrepancy may reflect the offsetting effects of brain opioid levels therapeutic efficacy, and withdrawal-related RLS symptoms, highlighting the complex dual nature of opioid action in RLS pathophysiology. These findings further suggest that the increase and decrease in opioid levels in the brain may promote dopamine secretion of different

patterns, leading to the development of addiction mechanisms. The enhancement of addiction mechanisms is both a result and a cause of restless leg syndrome.

Periodic Limb Movement Disorder and Neurophysiology

At the genetic, epidemiological, neurophysiological, and pharmacological response levels, RLS and periodic limb movement disorder demonstrate remarkable similarities[39–41]. This theory unifies these two conditions, proposing that they represent different manifestations of membrane potential abnormalities in the nervous system: sensory symptoms and motor symptoms.

Multi-system Involvement

Mice knocked out for BTBD9 showed motor restlessness, sensory alterations, decreased sleep, and altered serum iron levels, accompanied by cerebellar neuronal resting potential depolarization[42]. In mutant mice for MEIS1, hyperactivity was observed with a RLS-like circadian trend, associated with sensory alteration of functions modulated by dopaminergic networks, accompanied by increased risk of malignant arrhythmias[43]. The proportion of RLS is significantly increased in dialysis patients, which may be related to membrane potential abnormalities caused by dramatic fluctuations in blood electrolyte levels and the effects of toxins on Na+/K+-ATPase. RLS and periodic limb movement disorders can also be attributed to sleep apnea syndrome, which may be membrane potential abnormalities caused by hypoxia-induced Na+/K+-ATPase inhibition. In summary, this hypothesis can be used to explain the etiological heterogeneity of RLS and speculate that there may be manifestations of other system involvement, among which gastrointestinal and cardiac manifestations are most worthy of attention. Studies have shown that patients with RLS have a higher proportion of irritable bowel syndrome[28], which may aggravate iron absorption disorders further leading to iron deficiency and anemia, given that iron ions in the intestine may also experience transmembrane transport disorders. In terms of cardiac electrophysiology, studies have shown that the fQRS-T angle of RLS patients is significantly widened, suggesting cardiac repolarization abnormalities[27].

Therefore, the risk of malignant arrhythmias in patients with RLS deserves attention. There are also reports that RLS patients have abnormal manifestations of the autonomic nervous system[28].

Genetic Susceptibility

Cerebrospinal fluid analysis and autopsy findings in RLS patients reveal deficiencies in endogenous opioid. LDSC analysis demonstrated genetic correlation between the two conditions, while reverse MR analysis indicated that RLS was a risk factor for opioid use. These findings suggested that opioid use in RLS patients may be driven by genetic susceptibility. In other words, deficiency in endogenous opioid may predispose individuals to dependency, which can be either physiological or pathological. Physiological dependency can be viewed as a form of drug replacement therapy with sustained and stable therapeutic effects. However, the mechanisms underlying membrane potential abnormalities caused by secondary RLS may be more complex, potentially leading to pathological dependency due to continuous dose escalation when opioids fail to address the underlying problem. This underscored the critical importance of effective assessment and optimal dose management in opioid use among patients with RLS.

Hypothesis-Based Definition

RLS is not a disease per se, but rather a description of clinical manifestations. In fact, this may be a multi-system membrane potential polarization disorder caused by various etiologies. In the central nervous system, secondary neuronal synaptic hyperexcitability occurs, activating reward mechanisms for negative feedback regulation, which subsequently leads to reinforcement of addiction mechanisms. Although low-threshold ion channels throughout the body are affected, the human body's perceptual ability for synaptic low-threshold ion channels may be superior to other locations, leading to the high proportion of restless legs syndrome development. Motor symptoms manifest as periodic limb movement disorder, while peripheral

symptoms present as gastrointestinal dysfunction, iron absorption and transport disorders, cardiac electrophysiological abnormalities, and autonomic nervous system dysfunction. Considering the compensatory mechanisms of the dopaminergic system in the brain, it can be further classified into an asymptomatic compensated phase and a symptomatic decompensated phase. As is well known, sensory symptoms include not only discomfort but also an irresistible urge to move the lower limbs, complete relief after activity, and circadian rhythm changes. The complete relief after activity may be due to repolarization and hyperpolarization that occur in synapses after action potentials, while simultaneously, symptom relief reduces the dopaminergic burden of abnormally activated reward mechanisms, or symptom relief-dopamine secretion coupling phenomena occur. The circadian rhythm changes may be due to increased synaptic excitability leading to loss of control over circadian rhythm and light regulation of synapses, resulting in failure of nighttime synaptic excitability to decrease on schedule.

Limitations

Several limitations should be acknowledged in this study:

First, population specificity: The GWAS data used in this study were primarily derived from European populations, which may limit the generalizability of findings to other ethnic groups. Genetic variants and their effect sizes may differ across populations due to differences in linkage disequilibrium patterns, allele frequencies, and population-specific genetic architecture. Future studies should validate these findings in diverse populations, particularly Asian and African populations, to ensure broader applicability.

Second, temporal resolution limitations: While the temporal mediation model provides valuable insights into the time-dependent effects of opioids on RLS, the cross-sectional nature of GWAS data limits our ability to capture precise temporal dynamics. The model relies on theoretical assumptions about short-term versus

long-term effects, which, although biologically plausible, require validation through longitudinal studies with repeated measurements of metabolite levels and clinical outcomes.

Third, instrumental variable constraints and multiple testing: The analysis relied on a single instrumental variable (rs2618039 in KCND3) for opioids use, which, while statistically robust (F-statistic=30.6), may not capture the full spectrum of genetic influences on opioid response. Additionally, the relaxed significance threshold ($P<1\times10^{-5}$) used for CSF and brain metabolites, although necessary due to smaller sample sizes, may introduce some false-positive associations despite stringent confounder exclusion strategies. Furthermore, the mediation analysis involving 1,402 CSF and brain metabolites was not corrected for multiple testing, which could inflate the Type I error rate. However, this limitation is partially mitigated by the biological validation approach employed in this study, where findings are cross-validated through multiple independent analytical methods including enrichment analysis, colocalization analysis, and temporal mediation modeling, providing convergent evidence that strengthens the reliability of the identified associations.

Fourth, opioid use GWAS data limitations: The opioid use GWAS data lacked detailed clinical information regarding specific medication characteristics, including dosage, duration of treatment, frequency of administration, specific opioid formulations, and individual patient treatment histories. This limitation prevented the analysis from distinguishing between different patterns of opioid use (acute vs. chronic, low-dose vs. high-dose, specific opioid types) that may have had distinct genetic architectures and therapeutic implications. The phenotype definition encompasses all prescription opioids under ATC code N02A, potentially masking drug-specific genetic effects and dose-response relationships that could be clinically relevant for personalized treatment approaches.

Fifth, mechanistic validation: While the enrichment analysis provides strong evidence for potassium channel dysfunction and synaptic alterations, the proposed "multi-system membrane potential polarization disorder" hypothesis has not undergone targeted experimental validation through controlled laboratory studies. However, the hypothesis demonstrates remarkable explanatory power by providing a unified framework that coherently explains diverse clinical phenomena, including RLS symptomatology, therapeutic responses to different medications, comorbidity patterns, circadian rhythm alterations, iron metabolism disorders, and dopaminergic system compensatory changes. This multi-dimensional global explanatory capacity, combined with convergent evidence from genetic correlation analysis, bidirectional Mendelian randomization, mediation analysis, colocalization studies, and functional enrichment analysis, creates a mutually validating analytical framework that strengthens the credibility of the proposed mechanisms despite the absence of direct experimental confirmation.

Clinical and Research Implications

Hypothesis Significance and Scientific Impact

The "multi-system membrane potential polarization disorder" hypothesis provides a theoretical framework that integrates findings across neurology, pharmacology, and systems biology. In disciplinary research, this hypothesis offers a unified approach to understanding RLS pathophysiology through biophysical principles, potentially contributing to how movement disorders are studied. The integration of genetic, metabolic, and electrophysiological evidence may inform future research directions that consider multiple biological systems. In basic medical sciences, the hypothesis contributes to our understanding of membrane potential regulation in neurological function and suggests ion channel dysfunction as a potential mechanism in complex neurological disorders. This mechanistic insight may inform investigations of similar membrane potential-related conditions. In clinical recognition, the hypothesis

suggests a shift from symptom-based to mechanism-based understanding of RLS, which may inform the development of more targeted diagnostic and therapeutic approaches.

Diagnostic and Therapeutic Paradigm Transformation

This study suggests potential applications for precision medicine approaches in RLS management. The identification of endogenous opioid system dysfunction as a pathophysiological mechanism may inform the development of biomarker-based diagnostic tools. Endogenous opioid level detection represents a potential clinical application that could help identify patients who might benefit from targeted opioid therapy. This approach may shift opioid treatment from symptomatic management toward more targeted replacement therapy. The temporal mediation model provides insights for personalized treatment protocols that could optimize therapeutic benefits while minimizing risks. The metabolite-mediated mechanisms identified in this study may support the development of metabolite-guided treatment monitoring for assessing therapeutic response and detecting treatment-related complications.

Multi-System Clinical Implications and Preventive Medicine

The conceptualization of RLS as a multi-system membrane potential disorder has implications for preventive medicine and clinical surveillance. The hypothesis suggests that RLS patients might have increased risk for cardiac repolarization disorders and malignant arrhythmias due to membrane potential dysfunction affecting cardiac ion channels and electrical conduction systems. This insight may inform cardiovascular risk assessment in RLS patients and could justify cardiac monitoring protocols and arrhythmia screening, particularly in patients with severe symptoms or family history of sudden cardiac death. In epidemiological contexts, the multi-system nature of the disorder suggests that RLS studies should consider cardiovascular, metabolic, and sleep-related comorbidities. The identification of shared genetic and

metabolic pathways between RLS and other conditions may inform risk stratification and screening approaches for high-risk populations.

Drug Development and Therapeutic Innovation

The mechanistic insights from this study suggest several directions for therapeutic development. Potassium channel modulators represent a potential target class that could address underlying membrane potential dysfunction while avoiding tolerance and dependence issues associated with traditional opioid therapy. The identification of specific KCND3 variants as mediators suggests opportunities for genotype-guided drug development and precision therapeutics. Metabolite-targeted therapies represent another potential approach, with the four key mediating metabolites (CSF cortisol, urea, fructose, and brain ceramides) serving as both potential therapeutic targets and biomarkers. The temporal mediation model may inform the development of combination therapies that leverage protective mechanisms while mitigating risks. The multi-system nature of the disorder suggests potential for systems pharmacology approaches targeting multiple pathways. The hypothesis may also inform the design of biomarker-guided clinical trials using metabolite profiles and genetic markers for patient stratification and treatment optimization.

Conclusion

This comprehensive Mendelian randomization study provides the first genetic evidence for bidirectional causality between opioids use and RLS, establishing a novel temporal mediation framework that elucidates the complex therapeutic dynamics of opioid treatment. Through systematic analysis of 1,402 cerebrospinal fluid and brain metabolites, we identified four key mediators—CSF cortisol, urea, fructose, and brain ceramides—that explain the temporal evolution from significant short-term protective effects (OR=0.501, P=0.025) to attenuated long-term benefits due to metabolic dysregulation and tolerance mechanisms.

The functional enrichment analysis of 506 genes converges on a unified pathophysiological framework: the "multi-system membrane potential polarization disorder" hypothesis. This mechanistic model positions potassium channel dysfunction-mediated membrane potential polarization disorder as the central pathophysiological mechanism underlying RLS. The systematic downregulation of potassium channel function disrupts membrane repolarization capacity, leading to neuronal hyperexcitability and secondary synaptic adaptations, with dopaminergic system secondary change and enhanced addiction mechanism, that manifest as the characteristic sensory and motor symptoms.

Crucially, this hypothesis provides a coherent explanation for previously disparate clinical observations, including the iron-membrane potential interdependency that creates pathological feedback loops, the compensatory dopaminergic system hyperactivity with secondary receptor downregulation that reinforces addiction mechanisms, the therapeutic efficacy of diverse medication classes, and the multi-system manifestations encompassing cardiac repolarization abnormalities, gastrointestinal dysfunction, and autonomic nervous system involvement. The evidence for endogenous opioid deficiency, combined with the bidirectional causal relationship between RLS and opioids use, suggests that therapeutic opioid administration may represent a form of physiological replacement therapy rather than purely symptomatic treatment.

These findings fundamentally redefine RLS from a symptom-based neurological disorder to a mechanism-based multi-system condition, with implications for precision medicine approaches, cardiovascular risk assessment, and the development of targeted therapeutics addressing underlying membrane potential dysfunction. The temporal mediation model provides a framework for optimizing opioid therapy while the mechanistic insights suggest novel therapeutic targets, particularly potassium

channel modulators, that could address the underlying pathophysiology without the limitations of current symptomatic treatments.

References

1. Song, P., Wu, J., Cao, J., Sun, W., Li, X., Zhou, T., Shen, Y., Tan, X., Ye, X., Yuan, C., Zhu, Y., Rudan, I., & Global Health Epidemiology Research Group (GHERG). (2024). The global and regional prevalence of restless legs syndrome among adults: A systematic review and modelling analysis. *Journal of Global Health*, *14*. https://doi.org/10.7189/jogh.14.04113

2. Khachatryan, S. G., Ferri, R., Fulda, S., Garcia□Borreguero, D., Manconi, M., Muntean, M., & Stefani, A. (2022). Restless legs syndrome: Over 50□years of European contribution. *Journal of Sleep Research*, *31*(4). https://doi.org/10.1111/jsr.13632

3. Allen, R. P., Connor, J. R., Hyland, K., & Earley, C. J. (2009). Abnormally increased CSF 3-ortho-methyldopa (3-OMD) in untreated restless legs syndrome (RLS) patients indicates more severe disease and possibly abnormally increased dopamine synthesis. *Sleep Medicine*, *10*(1), 123–128. https://doi.org/10.1016/j.sleep.2007.11.012

4. Walters, A. S., Li, Y., Koo, B. B., Ondo, W. G., Weinstock, L. B., Champion, D., Afrin, L. B., Karroum, E. G., Bagai, K., & Spruyt, K. (2024). Review of the role of the endogenous opioid and melanocortin systems in the restless legs syndrome. *Brain*, *147*(1), 26–38. https://doi.org/10.1093/brain/awad283

5. Koo, B. B., Abdelfattah, A., Eysa, A., & Lu, L. (2024). The melanocortin and endorphin neuropeptides in patients with restless legs syndrome. *Annals of Neurology*, *95*(4), 688–699. https://doi.org/10.1002/ana.26876

6. Walters, A. S., Ondo, W. G., Zhu, W., & Le, W. (2009). Does the endogenous opiate system play a role in the restless legs syndrome?: A pilot post-mortem study. *Journal of the Neurological Sciences*, *279*(1–2), 62–65. https://doi.org/10.1016/j.jns.2008.12.022

7. Lyu, S., DeAndrade, M. P., Mueller, S., Oksche, A., Walters, A. S., & Li, Y. (2019). Hyperactivity, dopaminergic abnormalities, iron deficiency and anemia in an in vivo opioid receptors knockout mouse: Implications for the restless legs syndrome. *Behavioural Brain Research*, *374*, 112123. https://doi.org/10.1016/j.bbr.2019.112123

8. Silver, N., Allen, R. P., Senerth, J., & Earley, C. J. (2011). A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome. *Sleep Medicine*, *12*(5), 440–444. https://doi.org/10.1016/j.sleep.2010.11.002

9. Winkelman, J. W., Wipper, B., & Zackon, J. (2023). Long-term safety, dose stability, and efficacy of opioids for patients with restless legs syndrome in the national RLS opioid registry. *Neurology*, *100*(14). https://doi.org/10.1212/wnl.0000000000206855

10. Richmond, R. C., & Davey Smith, G. (2022). Mendelian randomization: Concepts and scope. *Cold Spring Harbor Perspectives in Medicine*, *12*(1), a040501. https://doi.org/10.1101/cshperspect.a040501

11. Wu, Y., Byrne, E. M., Zheng, Z., Kemper, K. E., Yengo, L., Mallett, A. J., Yang, J., Visscher, P. M., & Wray, N. R. (2019). Genome-wide association study of medication-use and associated disease in the UK biobank. *Nature Communications*, *10*(1). https://doi.org/10.1038/s41467-019-09572-5

12. Akçimen, F., Chia, R., Saez□Atienzar, S., Ruffo, P., Rasheed, M., Ross, J. P., Liao, C., Ray, A., Dion, P. A., Scholz, S. W., Rouleau, G. A., & Traynor, B. J. (2024). Genomic analysis identifies risk factors in restless legs syndrome. *Annals of Neurology*, *96*(5), 994–1005. https://doi.org/10.1002/ana.27040
13. Wang, C., Yang, C., Western, D., Ali, M., Wang, Y., Phuah, C.-L., Budde, J., Wang, L., Gorijala, P., Timsina, J., Ruiz, A., Pastor, P., Fernandez, M. V., Dominantly Inherited Alzheimer Network (DIAN), Perrin, R., The Alzheimer's Disease Neuroimaging Initiative (ADNI), Panyard, D. J., Engelman, C. D., Deming, Y., … Cruchaga, C. (2024). Genetic architecture of cerebrospinal fluid and brain metabolite levels and the genetic colocalization of metabolites with human traits. *Nature Genetics*, *56*(12), 2685–2695. https://doi.org/10.1038/s41588-024-01973-7
14. Schizophrenia Working Group of the Psychiatric Genomics Consortium, Bulik-Sullivan, B. K., Loh, P.-R., Finucane, H. K., Ripke, S., Yang, J., Patterson, N., Daly, M. J., Price, A. L., & Neale, B. M. (2015). LD score regression distinguishes confounding from polygenicity in genome-wide association studies. *Nature Genetics*, *47*(3), 291–295. https://doi.org/10.1038/ng.3211
15. Verbanck, M., Chen, C.-Y., Neale, B., & Do, R. (2018). Detection of widespread horizontal pleiotropy in causal relationships inferred from mendelian randomization between complex traits and diseases. *Nature Genetics*, *50*(5), 693–698. https://doi.org/10.1038/s41588-018-0099-7
16. Cohen, J. F., Chalumeau, M., Cohen, R., Korevaar, D. A., Khoshnood, B., & Bossuyt, P. M. M. (2015). Cochran's Q test was useful to assess heterogeneity in likelihood ratios in studies of diagnostic accuracy. *Journal of Clinical Epidemiology*, *68*(3), 299–306. https://doi.org/10.1016/j.jclinepi.2014.09.005
17. Bowden, J., Davey Smith, G., & Burgess, S. (2015). Mendelian randomization with invalid instruments: Effect estimation and bias detection through egger regression. *International Journal of Epidemiology*, *44*(2), 512–525. https://doi.org/10.1093/ije/dyv080
18. Zuber, V., Grinberg, N. F., Gill, D., Manipur, I., Slob, E. A. W., Patel, A., Wallace, C., & Burgess, S. (2022). Combining evidence from mendelian randomization and colocalization: Review and comparison of approaches. *American Journal of Human Genetics*, *109*(5), 767–782. https://doi.org/10.1016/j.ajhg.2022.04.001
19. De Vries, F., Bruin, M., Lobatto, D. J., Dekkers, O. M., Schoones, J. W., Van Furth, W. R., Pereira, A. M., Karavitaki, N., Biermasz, N. R., & Zamanipoor Najafabadi, A. H. (2020). Opioids and their endocrine effects: A systematic review and meta-analysis. *Journal of Clinical Endocrinology and Metabolism*, *105*(4), 1020–1029. https://doi.org/10.1210/clinem/dgz022
20. Wamsteeker Cusulin, J. I., & Bains, J. S. (2015). Embedded synaptic feedback in the neuroendocrine stress axis. *Journal of Neuroendocrinology*, *27*(6), 481–486. https://doi.org/10.1111/jne.12260
21. Tse, Y. C., Bagot, R. C., & Wong, T. P. (2012). Dynamic regulation of NMDAR function in the adult brain by the stress hormone corticosterone. *Frontiers in Cellular Neuroscience*, *6*. https://doi.org/10.3389/fncel.2012.00009
22. Flores Monar, G. V., Sanchez Cruz, C., & Calderon Martinez, E. (2025). Mindful eating: A deep insight into fructose metabolism and its effects on appetite regulation and brain function. *Journal of Nutrition and Metabolism*, *2025*(1). https://doi.org/10.1155/jnme/5571686
23. Brodowicz, J., Przegaliński, E., Müller, C. P., & Filip, M. (2018). Ceramide and its related neurochemical networks as targets for some brain disorder therapies. *Neurotoxicity Research*, *33*(2), 474–484. https://doi.org/10.1007/s12640-017-9798-6

24. Bryant, L., Doyle, T., Chen, Z., Cuzzocrea, S., Masini, E., Vinci, M. C., Esposito, E., Mazzon, E., Petrusca, D. N., Petrache, I., & Salvemini, D. (2009). Spinal ceramide and neuronal apoptosis in morphine antinociceptive tolerance. *Neuroscience Letters*, *463*(1), 49–53. https://doi.org/10.1016/j.neulet.2009.07.051
25. Drion, G., O'Leary, T., & Marder, E. (2015). Ion channel degeneracy enables robust and tunable neuronal firing rates. *Proceedings of the National Academy of Sciences*, *112*(38). https://doi.org/10.1073/pnas.1516400112
26. Gossard, T. R., Trotti, L. M., Videnovic, A., & St Louis, E. K. (2021). Restless legs syndrome: Contemporary diagnosis and treatment. *Neurotherapeutics*, *18*(1), 140–155. https://doi.org/10.1007/s13311-021-01019-4
27. Department of Cardiology, Adiyaman Training and Research Hospital, Adiyaman, Turkey, Abus, S., Kapici, Y., Department of Psychiatry, Kahta State Hospital, Adiyaman, Turkey, Ayhan, S., Department of Cardiology, Adiyaman Training and Research Hospital, Adiyaman, Turkey, Arik, A., & Department of Neurology, Adiyaman Training and Research Hospital, Adiyaman, Turkey. (2023). Elevated cardiovascular disease risk in patients with restless legs syndrome. *Alpha Psychiatry*, *24*(3), 95–99. https://doi.org/10.5152/alphapsychiatry.2023.221043
28. Acar, B., Acar, M., Acar, T., Varım, C., Alagöz, A., Demiryürek, E., Doğan Güngen, B., & Güzey Aras, Y. (2018). Patients with primary restless legs syndrome have higher prevalence of autonomic dysfunction and irritable bowel syndrome. *Singapore Medical Journal*, *59*(10), 539–544. https://doi.org/10.11622/smedj.2018010
29. Pasquadibisceglie, A., Bonaccorsi Di Patti, M. C., Musci, G., & Polticelli, F. (2023). Membrane transporters involved in iron trafficking: Physiological and pathological aspects. *Biomolecules*, *13*(8), 1172. https://doi.org/10.3390/biom13081172
30. Yehuda, S., & Youdim, M. B. H. (1984). The increased opiate action of β-endorphin in iron-deficient rats: The possible involvement of dopamine. *European Journal of Pharmacology*, *104*(3–4), 245–251. https://doi.org/10.1016/0014-2999(84)90399-6
31. Tanner, C. M., & Ostrem, J. L. (2024). Parkinson's disease. *New England Journal of Medicine*, *391*(5), 442–452. https://doi.org/10.1056/nejmra2401857
32. Estiar, M. A., Senkevich, K., Yu, E., Varghaei, P., Krohn, L., Bandres□Ciga, S., Noyce, A. J., Rouleau, G. A., & Gan□Or, Z. (2021). Lack of causal effects or genetic correlation between restless legs syndrome and parkinson's disease. *Movement Disorders*, *36*(8), 1967–1972. https://doi.org/10.1002/mds.28640
33. Gee, T. A., Weintraub, N. C., Lu, D., Phelps, C. E., Navratilova, E., Heien, M. L., & Porreca, F. (2020). A pain-induced tonic hypodopaminergic state augments phasic dopamine release in the nucleus accumbens. *Pain*, *161*(10), 2376–2384. https://doi.org/10.1097/j.pain.0000000000001925
34. Haddad, M., Pud, D., Treister, R., Suzan, E., & Eisenberg, E. (2018). The effects of a dopamine agonist (apomorphine) on experimental and spontaneous pain in patients with chronic radicular pain: A randomized, double-blind, placebo-controlled, cross-over study. *PLOS One*, *13*(4), e0195287. https://doi.org/10.1371/journal.pone.0195287
35. Wise, R. A., & Jordan, C. J. (2021). Dopamine, behavior, and addiction. *Journal of Biomedical Science*, *28*(1). https://doi.org/10.1186/s12929-021-00779-7
36. McCarter, S. J., Labott, J. R., Mazumder, M. K., Gebhard, J., Cunningham, J. L., Loukianova, L. L., Gilliam, W. P., & Lipford, M. C. (2023). Emergence of restless legs syndrome during opioid

discontinuation. *Journal of Clinical Sleep Medicine*, *19*(4), 741–748. https://doi.org/10.5664/jcsm.10436
37. Mackie, S. E., McHugh, R. K., McDermott, K., Griffin, M. L., Winkelman, J. W., & Weiss, R. D. (2017). Prevalence of restless legs syndrome during detoxification from alcohol and opioids. *Journal of Substance Abuse Treatment*, *73*, 35–39. https://doi.org/10.1016/j.jsat.2016.10.001
38. Schormair, B., Zhao, C., Bell, S., Didriksen, M., Nawaz, M. S., Schandra, N., Stefani, A., Högl, B., Dauvilliers, Y., Bachmann, C. G., Kemlink, D., Sonka, K., Paulus, W., Trenkwalder, C., Oertel, W. H., Hornyak, M., Teder-Laving, M., Metspalu, A., Hadjigeorgiou, G. M., … Winkelmann, J. (2024). Genome-wide meta-analyses of restless legs syndrome yield insights into genetic architecture, disease biology and risk prediction. *Nature Genetics*, *56*(6), 1090–1099. https://doi.org/10.1038/s41588-024-01763-1
39. Riccardi, S., Ferri, R., Garbazza, C., Miano, S., & Manconi, M. (2023). Pharmacological responsiveness of periodic limb movements in patients with restless legs syndrome: A systematic review and meta-analysis. *Journal of Clinical Sleep Medicine*, *19*(4), 811–822. https://doi.org/10.5664/jcsm.10440
40. Edelson, J. L., Schneider, L. D., Amar, D., Brink-Kjaer, A., Cederberg, K. L., Kutalik, Z., Hagen, E. W., Peppard, P. E., Tempaku, P. F., Tufik, S., Evans, D. S., Stone, K., Tranah, G., Cade, B., Redline, S., Haba-Rubio, J., Heinzer, R., Marques-Vidal, P., Vollenweider, P., … Mignot, E. (2023). The genetic etiology of periodic limb movement in sleep. *Sleep*, *46*(4). https://doi.org/10.1093/sleep/zsac121
41. Van Der Veen, S., Caviness, J. N., Dreissen, Y. E. M., Ganos, C., Ibrahim, A., Koelman, J. H. T. M., Stefani, A., & Tijssen, M. A. J. (2022). Myoclonus and other jerky movement disorders. *Clinical Neurophysiology Practice*, *7*, 285–316. https://doi.org/10.1016/j.cnp.2022.09.003
42. Lyu, S., Xing, H., DeAndrade, M. P., Perez, P. D., Yokoi, F., Febo, M., Walters, A. S., & Li, Y. (2020). The role of BTBD9 in the cerebellum, sleep-like behaviors and the restless legs syndrome. *Neuroscience*, *440*, 85–96. https://doi.org/10.1016/j.neuroscience.2020.05.021
43. Bouilloux, F., Thireau, J., Ventéo, S., Farah, C., Karam, S., Dauvilliers, Y., Valmier, J., Copeland, N. G., Jenkins, N. A., Richard, S., & Marmigère, F. (2016). Loss of the transcription factor Meis1 prevents sympathetic neurons target-field innervation and increases susceptibility to sudden cardiac death. *Elife*, *5*. https://doi.org/10.7554/elife.11627


Opioid use
Temporal Mediation Effect Model
Mediator
RLS
Membrane potential polarization disorder hypothesis


Cerebrospinal fluid fructose
Cerebrospinal fluid cortisol
Brain ceramide (d18:1/14:0, d16:1/16:0)*
Cerebrospinal fluid urea
-log10(P)
2.0
1.5
1.0
0.5
0.0
-2
-1
0
1
log2(FC)
Effect Type
Mediator Metabolites
No Significant Effect
Positive Effect
Negative Effect


Brain metabolite X-25979
Brain metabolite X-22773
Brain metabolite X-23038
Brain 4-hydroxy-nonenal-glutathione
Brain metabolite X-24432
Cerebrospinal fluid adenosine
Brain 15-KETE
Brain ceramide (d18:1/14:0, d16:1/16:0)*
Brain N-formylphenylalanine
Cerebrospinal fluid tartronate (hydroxymalonate)
Cerebrospinal fluid inosine
Cerebrospinal fluid ribitol
Cerebrospinal fluid O-sulfo-L-tyrosine
Cerebrospinal fluid erythritol
Cerebrospinal fluid ribonate
Cerebrospinal fluid 2R,3R-dihydroxybutyrate
Cerebrospinal fluid 2-methylcitrate/homocitrate
Cerebrospinal fluid 5-(galactosylhydroxy)-L-lysine
Cerebrospinal fluid mannonate*
Cerebrospinal fluid fructose
Cerebrospinal fluid 5,6-dihydrouracil
Cerebrospinal fluid mannitol/sorbitol
Cerebrospinal fluid hypoxanthine
Cerebrospinal fluid (N(1) + N(8))-acetylspermidine
Cerebrospinal fluid urea
Cerebrospinal fluid metabolite X-22162
Cerebrospinal fluid metabolite X-24728
Cerebrospinal fluid gluconate
Cerebrospinal fluid cortisol
Brain pelargonate (9:0)
Cerebrospinal fluid metabolite X-25422
Brain fructosyllysine
Brain lignoceroyl sphingomyelin (d18:1/24:0)
Brain N-acetylarginine
Brain 2,3-dihydroxy-5-methylthio-4-pentenoate (DMTPA)*
Cerebrospinal fluid trimethylamine N-oxide
Brain gamma-glutamylvaline
Cerebrospinal fluid xanthosine
Brain 1-(1-enyl-stearoyl)-2-oleoyl-GPE (P-18:0/18:1)
Brain glycosyl-N-(2-hydroxynervonoyl)-sphingosine (d18:1/24:1(2OH))*
Brain 4-acetamidobutanoate
Brain gamma-glutamylthreonine
Cerebrospinal fluid glycosyl ceramide (d18:2/24:1, d18:1/24:2)*
Brain 1-methyl-4-imidazoleacetate
Brain pyridoxate
Brain homocarnosine
Brain 7-HOCA
Brain carnosine
Brain metabolite X-21353
Brain saccharopine
Brain hippurate
Metabolites
0.2
0.5
1.0
2.0
5.0
10.0
OR(Wald ratio)
Metabolite Type
Brain
CSF


Cerebrospinal fluid fructose
Cerebrospinal fluid urea
Cerebrospinal fluid cortisol
Brain ceramide (d18:1/14:0, d16:1/16:0)*
-log10(P-value)
log2(Odds Ratio)
2.5
2.0
1.5
1.0
0.5
0.0
-1.5
-1.0
-0.5
0.0
0.5
1.0
Effect Type
Mediator Metabolites
No Significant Effect
Positive Effect
Negative Effect

Cerebrospinal fluid 3-methyl-2-oxobutyrate
Cerebrospinal fluid urea
Cerebrospinal fluid cortisol
Cerebrospinal fluid 3-hydroxy-3-methylglutarate
Brain FAD
Brain lactosyl-N-stearoyl-sphingosine (d18:1/18:0)*
Brain 1,2-dipalmitoyl-GPC (16:0/16:0)
Cerebrospinal fluid N-acetylaspartate (NAA)
Brain N6,N6,N6-trimethyllysine
Brain metabolite X-24425
Brain N-stearoylserine*
Brain ceramide (d18:1/14:0, d16:1/16:0)*
Brain 7-hydroxycholesterol (alpha or beta)
Brain stearoyl-docosahexaenoyl-glycerol (18:0/22:6) [2]*
Cerebrospinal fluid N-acetylallilin
Brain metabolite X-22162
Brain UDP-galactose
Brain heptadecasphingosine (d17:1)
Cerebrospinal fluid 4-acetamidophenylglucuronide
Cerebrospinal fluid 4-acetamidophenol
Brain N6-methyllysine
Brain dimethyl sulfone
Brain phenylalanylglycine
Cerebrospinal fluid heme
Brain cis-3,4-methyleneheptanoylcarnitine
Brain cysteine s-sulfate
Brain 1-methyl-5-imidazoleacetate
Brain phosphoenolpyruvate (PEP)
Brain retinol (Vitamin A)
Brain sphingomyelin (d18:2/18:1)*
Brain N-acetyltyrosine
Brain 2-hydroxydecanoate
Brain N2-methylguanosine
Cerebrospinal fluid alpha-hydroxyisovalerate
Cerebrospinal fluid 1-methyl-4-imidazoleacetate
Brain phosphoethanolamine (PE)
Brain 1-myristoyl-2-arachidonoyl-GPC (14:0/20:4)*
Cerebrospinal fluid 1-palmitoyl-2-linoleoyl-GPC (16:0/18:2)
Cerebrospinal fluid palmitoyl sphingomyelin (d18:1/16:0)
Cerebrospinal fluid 1,2-dipalmitoyl-GPC (16:0/16:0)
Brain lactate
Cerebrospinal fluid metabolite X-24337
Cerebrospinal fluid metabolite X-18887
Cerebrospinal fluid fructose
Metabolites
0.2
0.5
1.0
2.0
5.0
OR(Inverse variance weighted)
Metabolite Type
Brain
CSF


Cerebrospinal fluid fructose
Cerebrospinal fluid metabolite X-18887
Cerebrospinal fluid metabolite X-24337
Brain lactate
Cerebrospinal fluid 1,2-dipalmitoyl-GPC (16:0/16:0)
Cerebrospinal fluid palmitoyl sphingomyelin (d19:1/16:0)
Cerebrospinal fluid 1-palmitoyl-2-linoleoyl-GPC (16:0/18:2)
Brain 1-myristoyl-2-arachidonoyl-GPC (14:0/20:4)*
Brain phosphoethanolamine (PE)
Cerebrospinal fluid 1-methyl-4-imidazoleacetate
Cerebrospinal fluid alpha-hydroxyisovalerate
Brain N2-methylguanosine
Brain 2-hydroxydecanoate
Brain N-acetyltyrosine
Brain sphingomyelin (d18:2/18:1)*
Brain retinol (Vitamin A)
Brain phosphoenolpyruvate (PEP)
Brain 1-methyl-5-imidazoleacetate
Brain cystatine c-sulfate
Brain cis-3,4-methyleneheptanoylcarnitine
Cerebrospinal fluid heme
Brain phenylalanylglycine
Brain dimethyl sulfone
Brain N6-methyllysine
Cerebrospinal fluid 4-acetamidophenol
Cerebrospinal fluid 4-acetamidophenylglucuronide
Brain heptadecasphingosine (d17:1)
Brain UDP-galactose
Brain metabolite X-22162
Cerebrospinal fluid N-acetylallitin
Brain stearoyl-docosahexaenoyl-glycerol (18:0/22:6) [2]*
Brain 7-hydroxycholesterol (alpha or beta)
Brain ceramide (d18:1/14:0, d16:1/16:0)*
Brain N-stearoylserine*
Brain metabolite X-24425
Brain N6,N6,N6-trimethyllysine
Cerebrospinal fluid N-acetylaspartate (NAA)
Brain 1,2-dipalmitoyl-GPC (16:0/16:0)
Brain lactosyl-N-stearoyl-sphingosine (d18:1/18:0)*
Brain FAD
Cerebrospinal fluid 3-hydroxy-3-methylglutarate
Cerebrospinal fluid cortisol
Cerebrospinal fluid urea
Cerebrospinal fluid 3-methyl-2-oxobutyrate
Inverse variance weighted
MR Egger
Simple mode
Weighted median
Weighted mode
Odds Ratio
1.5
1.25
1.00
0.75
0.50
P-value
0.05
0.2
0.4
0.6
0.8
1.0


Forest Plot: Temporal Effects of Opioid Use on Restless Legs Syndrome
Masking Effect Analysis with Temporal Hypothesis and CSF Cortisol Combination (Odds Ratios)
Effect Type
Total Effect
Direct Effect
Direct+Cortisol
Short-term Total
Long-term Total
0.5
1.0
Odds Ratio (OR) - Log Scale
Significant (P < 0.05)
No
Yes
Error bars represent 95% confidence intervals. Dashed line indicates OR = 1 (null effect).
OR > 1: Increased risk; OR < 1: Decreased risk


All Genes GO Enrichment - Dot Plot
Top 20 most significant enrichment results
CC: potassium channel complex
CC: voltage-gated potassium channel complex
CC: cation channel complex
CC: monoatomic ion channel complex
CC: extrinsic component of membrane
CC: adherens junction
CC: basement membrane
MF: beta-catenin binding
CC: postsynaptic density membrane
BP: regulation of transmembrane transport
BP: axonogenesis
BP: regulation of neuron projection development
BP: potassium ion transmembrane transport
BP: axon guidance
BP: neuron projection guidance
BP: regulation of potassium ion transmembrane transport
BP: synapse assembly
BP: positive regulation of axonogenesis
BP: regulation of monoatomic ion transmembrane transport
CC: synaptic membrane
Enrichment Terms
2.5
3.0
3.5
4.0
-log10(p.adjust)
Gene Count
10
15
20
25
30
p.adjust
0.004
0.003
0.002
0.001
Data source: Excel table significant results


Upregulated Genes GO Enrichment - Dot Plot
Top 20 most significant enrichment results
CC: basement membrane
CC: postsynaptic specialization membrane
CC: postsynaptic density membrane
CC: adherens junction
CC: synaptic membrane
CC: postsynaptic specialization
CC: postsynaptic density
CC: postsynaptic membrane
CC: neuron to neuron synapse
CC: asymmetric synapse
CC: extrinsic component of postsynaptic membrane
CC: collagen-containing extracellular matrix
MF: GTPase regulator activity
MF: nucleoside-triphosphatase regulator activity
CC: dendritic spine
CC: neuron spine
CC: extrinsic component of synaptic membrane
CC: extrinsic component of plasma membrane
CC: perikaryon
CC: neuromuscular junction
Enrichment Terms
2
3
4
-log10(p.adjust)
p.adjust
0.04
0.03
0.02
0.01
Gene Count
4
8
12
16
Data source: Excel table significant results


Downregulated Genes GO Enrichment - Dot Plot
Top 20 most significant enrichment results
CC: voltage-gated potassium channel complex
CC: potassium channel complex
CC: cation channel complex
BP: regulation of potassium ion transmembrane transport
BP: regulation of transmembrane transport
MF: beta-catenin binding
MF: potassium channel regulator activity
BP: regulation of potassium ion transport
MF: channel regulator activity
MF: transporter regulator activity
BP: potassium ion transmembrane transport
BP: regulation of monoatomic ion transmembrane transport
BP: cardiac conduction
BP: regulation of monoatomic cation transmembrane transport
BP: potassium ion transport
MF: potassium channel activity
MF: ion channel regulator activity
BP: membrane repolarization
MF: transmembrane transporter binding
BP: magnesium ion transport
Enrichment Terms
1.5
2.0
2.5
3.0
-log10(p.adjust)
p.adjust
0.03
0.02
0.01
Gene Count
4
8
12
16
20
Data source: Excel table significant results


All Genes KEGG Enrichment - Dot Plot
Top 8 most significant enrichment results
Morphine addiction
Axon guidance
Human papillomavirus infection
GABAergic synapse
Serotonergic synapse
Cholinergic synapse
Thyroid hormone signaling pathway
Renin secretion
Enrichment Terms
1.50
1.75
2.00
2.25
2.50
-log10(p.adjust)
Gene Count
7.5
10.0
12.5
15.0
17.5
20.0
p.adjust
0.04
0.03
0.02
0.01
Data source: Excel table significant results